Dr. Bargmann will oversee a multi-billion dollar effort over the coming years to develop and implement a strategy to unlock understanding of the human body down to the cellular level. She will also continue as a tenured professor conducting research at Rockefeller.
On a recent Saturday, the Rockefeller campus was transformed into a vast science exhibit with more than 35 interactive stations. Each year, this popular event draws families from across New York City to experience the authentic process of science.
Modeled on New York City’s 311, NotifyRU acts as a central portal for a myriad of lower-level issues that arise on campus.
Rockefeller has the highest percentage of frequently cited scientific publications among 842 leading universities worldwide, according to a survey created by the Center for Science and Technology Studies of Leiden University. The ranking is based on publications indexed in a Thomson Reuters database between 2011 and 2014.
Since its inception in 2014, the Robertson Therapeutic Development Fund has supported translational research projects in 35 different labs. The fund gives Rockefeller scientists resources to develop basic research discoveries into new medical therapies, diagnostics, and devices. A request for proposals for the next round of funding will be issued in June.
The 19.1 million-pound steel skeleton will be hoisted into place from barges in the East River during the early morning hours this summer.
Get ready for the annual workplace health event, a feature of the university’s wellness program, which begins May 25 and takes participants on a virtual global journey.
When complete, the revamped website will better advance the university’s strategic communication goals and will be easily navigable across a variety of different devices.
IT has unveiled its inventory dashboard and support matrix, two resources it hopes will help streamline the way labs and departments manage their technology purchases, and better plan software updates.
The Tri-Institutional Therapeutics Discovery Institute is expanding its scope to support the development of antibody therapies, which are successfully used to treat a growing list of diseases.